The estimated Net Worth of Stewart Fisher is at least $4.47 Milion dollars as of 30 August 2023. Dr Fisher owns over 2,250 units of C4 Therapeutics stock worth over $628,422 and over the last 4 years he sold CCCC stock worth over $3,841,911.
Dr has made over 8 trades of the C4 Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,250 units of CCCC stock worth $13,500 on 30 August 2023.
The largest trade he's ever made was selling 68,315 units of C4 Therapeutics stock on 29 July 2021 worth over $3,074,175. On average, Dr trades about 11,894 units every 71 days since 2020. As of 30 August 2023 he still owns at least 104,737 units of C4 Therapeutics stock.
You can see the complete history of Dr Fisher stock trades at the bottom of the page.
Dr. Stewart Fisher is the Chief Scientific Officer at C4 Therapeutics.
Dr Fisher is 54, he's been the Chief Scientific Officer of C4 Therapeutics since . There are 2 older and 3 younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics, Inc. is Dr. Kenneth C. Anderson M.D., Ph.D., 70, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
Stewart's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at C4 Therapeutics have traded over $12,678,122 worth of C4 Therapeutics stock and bought 27,275 units worth $336,287 . The most active insiders traders include Marc A Cohen, Alain J Cohen a Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of $56,874. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth $45,000.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics executives and other stock owners filed with the SEC include: